|
|
- 2018
冠状动脉支架内再狭窄发生机制的研究进展
|
Abstract:
摘要：经皮冠状动脉介入术是目前治疗冠状动脉粥样硬化性心脏病的主要有效的治疗手段，血管支架尤其是药物洗脱支架极大程度上改善了冠心病患者的疗效和预后。与支架相关的病理主要表现为支架内再狭窄引起的进行性心绞痛和支架内血栓导致的急性心肌梗死。支架内再狭窄是由生物、机械、技术及与患者自身相关的复杂相互作用介导形成的病理性新生内膜增生，有关其发病机制的研究正不断深入。本文通过血管内皮损伤、血管平滑肌细胞增殖迁移、血管外基质重构、炎症反应以及新生动脉内膜粥样硬化等方面对其进行综述，深入探讨其形成的影响因素及临床意义。
ABSTRACT: Percutaneous coronary intervention is one of the main means for the treatment of coronary heart disease (CAD); especially drug-eluting stent has been greatly improved the effect and prognosis of the CAD patients. Stent-related pathology is mainly manifested by in-stent restenosis(ISR) and in-stent thrombosis. ISR, a pathologic response to injury is due to the complex interaction of biological, mechanical, technological and patient-related factors. Its pathogenesis has been studied deeply in these years. In this report, we review the mechanism of ISR in different aspects and discuss its influencing factors and clinicial significance
| [1] | HAO PP, CHEN YG, WANG XL, et al. Efficacy and safety of drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: A meta-analysis of randomized controlled trials[J]. Tex Heart Inst J, 2010, 37(5):516-524. |
| [2] | FARB A, SHROFF S, JOHN M, et al. Late arterial responses (6 and 12 months) after 32P beta-emitting stent placement: sustained intimal suppression with incomplete healing[J]. Circulation, 2011, 103(14):1912-1919. |
| [3] | INOUE T, UCHIDA T, YAGUCHI I, et al. Stent-induced expression and activation of the leukocyte integrin Mac-1 is associated with neointimal thickening and restenosis[J]. Circulation, 2014, 107(13):1757-1763. |
| [4] | MASSBERG S, GAWAZ M, GRUNER S, et al. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall ？？in vivo？？[J]. J Exp Med, 2003, 197(1):41-49. |
| [5] | KATSAROS KM, KASTL SP, ZORN G, et al. Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and-9[J]. J Am Coll Cardiol, 2010, 3(2):90-97. |
| [6] | DEMYANTS S, TENTZERIS I, JARAI R, et al. An increase of interleukin-33 serum levels after coronary stent implantation is associated with coronary in-stent restenosis[J]. Cytokine, 2014, 3(2):65-70. |
| [7] | SPEIDL WS, KATSAROS KM, KASTL SP, et al. Coronary late lumen loss of drug eluting stents is associated with increased serum levels of the complement components C3a and C5a[J]. Atherosclerosis, 2010, 20(8):285-289. |
| [8] | 丁法明，王聪霞，张春艳，等. 基质金属蛋白酶-和白介素-18在冠心病及糖尿病大血管并发症中的作用[J]. 西安交通大学学报(医学版), 2014, 35(5):646-650. |
| [9] | ADIGUZEL E,AHMAD PJ, FRANCO C, et al. Collagens in the progression and complications of atherosclerosis[J]. Vasc Med, 2009, 1(4):73-89. |
| [10] | NAKAZAWA G, LADICH E, FINN AV, et al. Pathophysiology of vascular healing and stent mediated arterial injury[J]. Euro Intervention, 2008, 4(2), Suppl C:C7-10. |
| [11] | NAKANO M, OTSUKA F, YAHAGI K, et al. Human autopsy study of drug-eluting stents restenosis: Histomorphological predictors and neointimal characteristics[J]. Eur Heart J, 2013, 34(5):3304-3313. |
| [12] | TABS I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: The importance of lesion stage and phagocytic efficiency[J]. Arterioscl Throm Vas, 2005, 25(5):2255-2264. |
| [13] | NAKAZAWA G, FINN AV, JONER M, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: An autopsystudy[J]. Circulation, 2008, 118(9):1138-1145. |
| [14] | IP JH, FUSTER V, BADIMON L, et al. Syndromes of accelerated atherosclerosis: Role of vascular injury and smooth muscle cell proliferation[J]. J Am Coll of Cardiol, 1990, 15(7):1667-1687. |
| [15] | VAN DER HEIDEN K, GIJSEN FJ, NARRACOTT A, et al. The effects of stenting on shear stress: Relevance to endothelial injury and repair[J]. Cardiovasc Res, 2013, 99(2):269-275. |
| [16] | RUDIJANTO A. The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis[J]. Acta Med Indones, 2007, 39(2):86-93. |
| [17] | SONG Z, LI G. Role of specific microRNAs in regulation of vascular smooth muscle cell differentiation and the response to injury[J]. J Cardiovasc Transl, 2010, 3(3):246-250. |
| [18] | ASADA H, PASZKOWIAK J, TESO D, et al. Sustained orbital shear stress stimulates smooth muscle cell proliferation via the extracellular signal-regulated protein kinase 1/2 pathway[J]. J Vasc Surg, 2005, 42(4):772-780. |
| [19] | KOZINSKI M, KRZEWINA-KOWALSKA A, KUBICA J, et al. Percutaneous coronary intervention triggers a systemic inflammatory response in patients treated for in-stent restenosis--Comparison with stable and unstable angina[J]. Inflamm Res, 2012, 54(5):187-193. |
| [20] | GERTHOFFER WT. Mechanisms of vascular smooth muscle cell migration[J]. Circ Res, 2007, 100(5):607-621. |
| [21] | RZUCIDLO EM. Signaling pathways regulating vascular smooth muscle cell differentiation[J]. Vascular, 2013, 17 Suppl 1(S15-20). |
| [22] | DIEZ-JUAN A, CASTRO C, EDO MD, et al. Role of the growth suppressor p27Kip1 during vascular remodeling[J]. Curr Vasc Pharmacol, 2013, 1(1):99-106. |
| [23] | VENDROV AE, HAKIM ZS, MADAMANCHI NR, et al. Atherosclerosis is attenuated by limiting superoxide generation in both macrophages and vessel wall cells[J]. Arterioscl Throm Vas, 2015, 27(12):2714-2721. |
| [24] | NICCOLI G, SCHIAVINO D, BELLONI F, et al. Pre-intervention eosinophilcationic protein serum levels predict clinical outcomes following implantation of drug-eluting stents[J]. Eur Heart J, 2009, 30(2):1340-1347. |
| [25] | JUKEMA JW, VERSCHUREN JJ, AHMED TA, et al. Restenosis after PCI. Part 1: pathophysiology and risk factors[J]. Nat Rev Cardiol, 2013, 9(1):53-62. |
| [26] | CINES DB, POLLAK ES, BUCK CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders[J]. Blood, 1998, 91(10):3527-3561. |
| [27] | DURAISWAMY N, JAYACHANDRAN B, BYRNE J, et al. Spatial distribution of platelet deposition in stented arterial models under physiologic flow[J]. Ann Biomed Eng, 2015, 33(12):1767-1777. |
| [28] | JI R, CHENG Y, YUE J, et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation[J].Circ Res, 2007, 100(11):1579-1588. |
| [29] | CHEN J, YIN H, JIANG Y, et al. Induction of microRNA-1 by myocardin in smooth muscle cells inhibits cell proliferation[J]. Arterioscl Throm Vas, 2011, 31(2):368-375. |
| [30] | LIU X, CHENG Y, ZHANG S, et al. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia[J]. Circ Res, 2012, 104(4):476-487. |
| [31] | RAITOHARJU E, LYYTIKAINEN LP, LEVULA M, et al. miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the tampere vascular study[J]. Atherosclerosis, 2011, 219(1):211-217. |
| [32] | MOZAFFARIAN D, BENJAMIN EJ, GO AS, et al. Heart disease and stroke statistics―2016 update: A report from the American Heart Association[J]. Circulation, 2016, 133(4):e38-360. |
| [33] | KANG SJ, MINTZ GS, PARK DW, et al. Mechanisms of in-stent restenosis after drug-eluting stent implantation: Intravascular ultrasound analysis[J]. Circ Cardiovasc Interv, 2011, 4(1):9-14. |
| [34] | THEODOROPOULOS K, MENNUNI MG, DANGAS GD, et al. Resistant in-stent restenosis in the drug eluting stent era[J]. Catheter Cardio Inte, 2016, 88(5):777-785. |
| [35] | MEHRAN R, DANGAS G, ABIZAID AS, et al. Angiographic patterns of in-stent restenosis: Classification and implications for long-term outcome[J]. Circulation, 1999, 100(18):1872-1878. |
| [36] | CORBETT SJ, COSGRAVE J, MELZI G, et al. Patterns of restenosis after drug-eluting stent implantation: Insights from a contemporary and comparative analysis of sirolimus- and paclitaxel-eluting stent[J]. Eur Heart J, 2006, 27(19):2330-2337. |
| [37] | KASTRATI A, SCHOMIG A, DIETZ R, et al. Time course of restenosis during the first year after emergency coronary stenting[J]. Circulation, 1993, 87(18):1498-1505. |
| [38] | GUILDFORD AL, STEWART HJ, MORRIS C, et al. Substrate-induced phenotypic switches of human smooth muscle cells: An ？？in vitro？？ study of in-stent restenosis activation pathways[J]. J R Soc Interface, 2011, 8(58):641-649. |
| [39] | MUKAI HY, NINOMIYA H, OHTANI K,et al. Major basic protein binding to thrombomodulin potentially contributes to the thrombosis in patients with eosinophilia[J]. Brit J Haematol, 1995, 90(11):892-899. |
| [40] | VIRMANI R, GUAGLIUMI G, FARB A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious?[J]. Circulation, 2014, 109(6):701-705. |
| [41] | KANG WC, AHN TH, MOON CI, et al. Comparison of inflammatory markers and angiographic outcomes after implantation of sirolimus and paclitaxel eluting stents[J]. Heart, 2009, 9(5):970-975. |
| [42] | FARB A, KOLODGIE FD, HWANG JY, et al. Extracellular matrix changes in stented human coronary arteries[J]. Circulation, 2004, 1(10):940-947. |
| [43] | BEREZIKOV E. Evolution of microRNA diversity and regulation in animals[J]. Nat Rev Genet, 2011, 12(12):846-860. |
| [44] | ALBINSSON S, SUAREZ Y, SKOURA A, et al. MicroRNAs are necessary for vascular smooth muscle growth, differentiation, and function[J]. Arterioscl Throm Vas, 2010, 30(6):1118-1126. |
| [45] | ALBINSSON S, SESSA WC. Can microRNAs control vascular smooth muscle phenotypic modulation and the response to injury?[J]. Physiol Genomics, 2011, 43(10):529-533. |
| [46] | CHAN MC, HILYARD AC, WU C, et al. Molecular basis for antagonism between PDGF and the TGFbeta family of signalling pathways by control of miR-24 expression[J]. EMBO J, 2012, 29(3):559-573. |
| [47] | OTSUKA F, FINN AV, YAZDANI SK, et al. The importance of the endothelium in atherothrombosis and coronary stenting[J]. Nat Rev Cardiol, 2012, 9(2):439-453. |
